R
Ravi Anand
Researcher at Novartis
Publications - 61
Citations - 6041
Ravi Anand is an academic researcher from Novartis. The author has contributed to research in topics: Rivastigmine & Tolerability. The author has an hindex of 30, co-authored 59 publications receiving 5782 citations. Previous affiliations of Ravi Anand include Indiana University & Organon International.
Papers
More filters
Journal ArticleDOI
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Herbert Y. Meltzer,Larry Alphs,Alan I. Green,A. Carlo Altamura,Ravi Anand,Alberto Bertoldi,Marc Bourgeois,Guy Chouinard,M. Zahur Islam,John M. Kane,Ranga Krishnan,Jean-Pierre Lindenmayer,Steven G. Potkin,Saide Altinsan,Siemion Altman,Likiana Avigo,Richard Balon,Vanda Benešová,Luis Bengochea,István Bitter,Elisabeth Bokowska,Bernardo Carpiniello,Daniel E. Casey,Giovanni B. Cassano,James C.-Y. Chou,Libor Chvila,Jean Dalery,Pedro L. Delgado,Liliana Dell'Osso,Carl Eisdorfer,Robin Emsley,Dawn Eng,Tom A. Fahy,Vera Folnegovic,Sophie Frangou,Pedro Gargoloff,Alberto Giannelli,Ira D. Glick,Richard Greenberg,George T. Grossberg,Doris Gundersen,Hannale Heila,George Hsu,Naveed Iqbal,Miro Jakovljević,Richard C. Josiassen,Akos Kassaifarkas,Robert Kerwin,Frederic Khidichian,Mary Ann Knesevich,Jack S. Krasuski,Vinod Kumar,Veronica W. Larach,Michael D. Lesem,Shôn Lewis,Pierre-Michel Llorca,H. Edward Logue,Stephen Martin,Muriel Maurel-Raymondet,Laszlo Mod,Eva Morik,Carlos Morra,Ann M. Mortimer,Mojtaba Noursalehi,Gyorgy Ostorharics-Horvath,Ivo Paclt,Jörg Pahl,Linda Pestreich,J. L. Peters,Rosario Pioli,Michael G. Plopper,Thomas Posever,Mark Hyman Rapaport,Delbert Robinson,Carlo Andrea Robotti,Harry Rohme,Frédéric Rouillon,David A. Sack,Isaac Sakinsofsky,Phillip Seibel,George M. Simpson,Nancy Temkin,Oladapo Tomori,Santha Vaidain,Zdeòka Vyhnándová,Frederick Young,Daniel L. Zimbroff,Marie Agathe Zimmerman +87 more
TL;DR: It is suggested that clozapine therapy significantly reduces suicidal behavior in patients with schizophrenia and schizoaffective disorder at high risk for suicide, and use of clozAPine in this population should lead to a significant reduction in suicidal behavior.
Journal ArticleDOI
Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
Ian G. McKeith,Teodoro Del Ser,PierFranco Spano,Murat Emre,Keith Wesnes,Ravi Anand,Ana Cicin-Sain,Roberto Ferrara,René Spiegel +8 more
TL;DR: Rivastigmine 6-12 mg daily produces statistically and clinically significant behavioural effects in patients with Lewy-body dementia, and seems safe and well tolerated if titrated individually.
Journal ArticleDOI
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Michael Rösler,Ravi Anand,Ana Cicin-Sain,Serge Gauthier,Yves Agid,Peter Dal-Bianco,Hannes B. Stähelin,Richard Hartman,Marguirguis Gharabawi +8 more
TL;DR: In this paper, the effects of rivastigmine on the core domains of Alzheimer9s disease were assessed in a 6-month trial with 725 patients with mild to moderately severe probable Alzheimer 9s disease diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition.
Journal ArticleDOI
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
TL;DR: By 52 weeks, patients originally treating with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.
Journal ArticleDOI
Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system.
Keith Wesnes,Ian G. McKeith,Roberto Ferrara,Murat Emre,T. Del Ser,PierFranco Spano,Ana Cicin-Sain,Ravi Anand,René Spiegel +8 more
TL;DR: Benefits to cognitive function were accompanied by a significant improvement of the other primary outcome measure, the Neuropsychiatric Inventory, three weeks after discontinuation of rivastigmine, most parameters of cognitive performance returned to predrug levels.